Treatment Preferences of Patients With Relapsed or Refractory Multiple Myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: Results From a Discrete Choice Experiment
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702501/
Newer treatment options for relapsed/refractory multiple myeloma (RRMM) with efficacy and safety profiles that differ from traditional therapies have facilitated personalized management strategies to optimize patient outcomes.
This robust, quantitative patient preference study found that treatment preferences were strongly driven by maximizing treatment efficacy (ORR and OS) compared with other treatment characteristics related to therapeutic administration methods and risk of specified side effects.
Survival in Multiple Myeloma and SARS-COV-2 Infection Through the COVID-19 Pandemic: Results From the EPICOVIDEHA Registry
Source : https://pubmed.ncbi.nlm.nih.gov/38050405/
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological...
The majority of patients (52%) with MM showed a critical/severe infection requiring hospitalization (64%). Overall, these data suggest that patients with MM remain vulnerable to SARS-CoV-2 infection even in the vaccination era, but also that these patients have progressively improved their OS throughout the different viral phases of...
Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: a Case Report
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673342/
The burden of melanoma is increasing globally. Despite the use of immunotherapy and targeted therapy, the prognosis of metastatic melanoma remains relatively poor. The integration of comprehensive molecular profiling can...
The presented case highlights the need to test broadly in clinical practice considering that they can impact prognosis when standard of care fails.
Bridging Treatment Prior to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
Source : https://pubmed.ncbi.nlm.nih.gov/38036424/
Autologous patient-derived adoptive T-cell therapies have revolutionized the management of relapsed multiple myeloma (MM). However, the current manufacturing and quality control processes result in lengthy vein-to-vein time, making bridging therapy...
In this perspective piece, the authors provide their approach and considerations while selecting an optimal bridging regimen before autologous chimeric antigen receptor T-cell therapy.
Multi-Scale Geometric Network Analysis Identifies Melanoma Immunotherapy Response Gene Modules
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690163/
Melanoma response to immune-modulating therapy remains incompletely characterized at the molecular level. In this study, we assess melanoma immunotherapy response using a multi-scale network approach to identify gene modules with...
Using gene expression data of melanoma before and after treatment with nivolumab, researchers modeled gene expression changes in a correlation network and measured a key network geometric property, dynamic Ollivier-Ricci curvature, to distinguish critical edges within the network and reveal multiscale treatment-response gene communities.